Lipocine Inc. (LPCN)
| Market Cap | 93.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.00M |
| Shares Out | 88.29M |
| EPS (ttm) | -0.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 354,556 |
| Open | 1.08 |
| Previous Close | 1.09 |
| Day's Range | 1.05 - 1.09 |
| 52-Week Range | 0.98 - 2.42 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 4.75 (+348.1%) |
| Est. Earnings Date | Nov 9, 2021 |
About LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailabili...
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for Lipocine stock is "Buy." The 12-month stock price forecast is 4.75, which is an increase of 348.11% from the latest price.
News
Lipocine, Antares Ink Licensing Pact For Testosterone Replacement Therapy In US
Lipocine Inc (NASDAQ: LPCN) has entered into an exclusive licensing agreement with Antares Pharma Inc (NASDAQ: ATRS) to commercialize Tlando in the U.S. Tlando is an oral testosterone product for testo...
Penny Stocks To Watch Today As Buying Drives ADMP, IO, LPCN & Others
A jump in penny stock prices has retail traders cashing out on big gains. The post Penny Stocks To Watch Today As Buying Drives ADMP, IO, LPCN & Others appeared first on Penny Stocks to Buy, Picks, News...
Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO®
SALT LAKE CITY, Oct. 18, 2021 /PRNewswire/ -- Under the terms of Agreement Lipocine to receive: Up to $21.0 million in licensing fees, including $11.0 million payable immediately and $10.0 million to be...
Lipocine to Present at The H.C. Wainwright 5th Annual NASH Investor Conference
SALT LAKE CITY, Oct. 5, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will ...
Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®
SALT LAKE CITY, Sept. 28, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the U.S. Food and Dr...
Lipocine to Present at The Cantor Fitzgerald Virtual Global Healthcare Conference
SALT LAKE CITY, Sept. 20, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company wil...
Lipocine to Present at The H.C. Wainwright 23rd Annual Global Investment Conference
SALT LAKE CITY , Sept. 1, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company wil...
Top Reddit Penny Stocks to Watch in September 2021
Are these 3 Reddit penny stocks on your watchlist right now? The post Top Reddit Penny Stocks to Watch in September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....
Top Penny Stocks Analysts Say To Buy, Targets Up To 200% Right Now
Penny stocks with high marks from analysts right now. The post Top Penny Stocks Analysts Say To Buy, Targets Up To 200% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...
Lipocine Meets Resolution Regulatory Endpoint In Mid-Stage NASH Trial
Lipocine Inc (NASDAQ: LPCN) has announced topline 36-week results from its Phase 2 proof of concept LiFT study investigating LPCN 1144 in Non-Alcoholic Steatohepatitis (NASH). LPCN 1144 comprises an ora...
Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study
SALT LAKE CITY, Aug. 25, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive topline 36-w...
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021
SALT LAKE CITY, Aug. 5, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for ...
Lipocine Stock Jumps On Litigation Settlement With Clarus Therapeutics
Lipocine Inc (NASDAQ: LPCN) has entered into a settlement and license agreement with Clarus Therapeutics to resolve claims in the ongoing intellectual property litigation and interference proceeding. U...
Lipocine Announces Settlement With Clarus Therapeutics
SALT LAKE CITY, July 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered i...
Lipocine To Present At The Ladenburg Thalmann Healthcare Conference
SALT LAKE CITY, July 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will ...
Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital Event
SALT LAKE CITY, June 23, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data wi...
Lipocine To Present At The Raymond James Human Health Innovation Conference
SALT LAKE CITY, June 16, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will...
Lipocine To Start Testing Neuro-Steroid Candidate In Postpartum Depression Patients
The FDA has signed off Lipocine Inc's (NASDAQ: LPCN) Investigational New Drug Application (IND) to initiate a Phase 2 study to evaluate LPCN 1154 for the treatment of postpartum depression (PPD) in adul...
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
SALT LAKE CITY, June 14, 2021 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food an...
Lipocine to Present at the Lytham Partners Summer 2021 Investor Conference
SALT LAKE CITY, June 7, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will ...
Clarus Therapeutics Wins Jatenzo Patent Infringement Case Brought By Lipocine
The U.S. District Court for the District of Delaware has granted Clarus Therapeutics' motion for summary judgment against remaining patents in a patent infringement case brought by Lipocine Inc (NASDAQ:...
Summary Judgment Ruling in Patent Infringement Lawsuit
SALT LAKE CITY, May 26, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the United States...
Clarus Therapeutics Defeats Lipocine's Patent Infringement Lawsuit On Summary Judgment
NORTHBROOK, Ill., May 25, 2021 /PRNewswire/ -- Today, Federal Circuit Judge William C.
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021
SALT LAKE CITY, May 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for t...
